All In Biotech

Drug Trial Radar · NCT06220604

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 731 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

731

Actual

Start

Mar 9, 2024

Primary completion

Nov 15, 2024

Study completion Sep 20, 2027

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jan 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.

Conditions

  • Plaque Psoriasis

Interventions

  • JNJ-77242113Drug

    JNJ-77242113 will be administered orally.

  • JNJ-77242113 Matching PlaceboDrug

    JNJ-77242113 matching placebo will be administered orally.

  • DeucravacitinibDrug

    Deucravacitinib will be administered orally.

  • Deucravacitinib Matching PlaceboDrug

    Deucravacitinib matching placebo will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16Time frame: Week 16
  2. Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 16Time frame: Week 16

Locations

128 sites in 11 countries. Site status is shown where the registry gives one.

  • Alliance Dermatology and MOHS Center P C

    Phoenix, Arizona

  • California Dermatology & Clinical Research Institute

    Encinitas, California

  • T Joseph Raoof Md Inc

    Encino, California

  • UCSF Fresno

    Fresno, California

  • University of California Los Angeles - Division of Dermatology

    Los Angeles, California

  • Wallace Medical Group, Inc

    Los Angeles, California

  • Dermatologist Medical Group of North County, Inc.

    Oceanside, California

  • Miami Dermatology And Laser Institute

    Miami, Florida

  • Bioclinical Research Alliance Inc.

    Miami, Florida

  • Forcare Clinical Research Inc

    Tampa, Florida

  • Southeast Dermatology Specialists

    Douglasville, Georgia

  • Arlington Dermatology

    Rolling Meadows, Illinois

  • Skin Sciences, PLLC

    Louisville, Kentucky

  • Qualmedica Research

    Owensboro, Kentucky

  • DermAssociates, PC

    Rockville, Maryland

  • Metro Boston Clinical Partners

    Brighton, Massachusetts

  • ActivMed Practices and Research

    Methuen, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Great Lakes Research Group

    Bay City, Michigan

  • The Derm Institute of West Michigan

    Caledonia, Michigan

  • Hamzavi Dermatology

    Canton, Michigan

  • Somerset Skin Centre

    Troy, Michigan

  • Cleaver Dermatology

    Kirksville, Missouri

  • Bexley dermatology research

    Bexley, Ohio

  • Essential Medical Research

    Tulsa, Oklahoma

  • Oregon Dermatology & Research Center

    Portland, Oregon

  • Paddington Testing Co, Inc.

    Philadelphia, Pennsylvania

  • Clinical Research Center of the Carolinas LLC

    Charleston, South Carolina

  • Palmetto Clinical Trial Services, LLC

    Greenville, South Carolina

  • Arlington Research Center, Inc.

    Arlington, Texas

  • UT Southwestern Medical Center

    Dallas, Texas

  • Dermatology Clinical Research Center of San Antonio

    San Antonio, Texas

  • Center for Clinical Studies

    Webster, Texas

  • Cope Family Medicine - Ogden Clinic

    Bountiful, Utah

  • Springville Dermatology CCT Research

    Springville, Utah

  • Kalo Clinical Research

    West Valley City, Utah

  • Virginia Dermatology Skin Cancer Center Pllc

    Norfolk, Virginia

  • The Skin Centre

    Benowa, Australia

  • Monash Medical Centre

    Clayton, Australia

  • Premier Specialists

    Kogarah, Australia

Showing 40 of 128 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.